---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Esketamine and ketamine"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Esketamine and ketamine. Topics: CANMAT guideline: second-line adjunctive ketamine and intranasal esketamine, VA/DoD guideline: ketamine or esketamine after several pharmacologic trials, NICE guideline: esketamine nasal spray not recommended, ICER assessment: esketamine and intravenous ketamine as comparators for psilocybin, and 13 further topics. 17 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/esketamine-and-ketamine"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Esketamine and ketamine

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 Esketamine and Ketamine

<a id="topic-2.2.2.1.5-1"></a>

### CANMAT guideline: second-line adjunctive ketamine and intranasal esketamine

> “which is approved by several regulatory agencies as an add-on treatment to an SSRI/SNRI or other antidepressant, for patients failing at least 2 adequate antidepressant trials.”
> “There is also growing evidence for relapse-prevention efficacy for both medications, with maintenance doses administered every 1 to 4 weeks”
> “However, side effect potential and feasibility issues (i.e., the required monitoring of blood pressure and dissociative side effects) have downgraded adjunctive ketamine and intranasal esketamine to second-line recommendation.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.5-2"></a>

### VA/DoD guideline: ketamine or esketamine after several pharmacologic trials

> “For patients with MDD who have not responded to several adequate pharmacologic trials, we suggest ketamine or esketamine as an option for augmentation.”
> “(Weak for | Reviewed, New-replaced)”
> “Ketamine is a glutamate N-methyl-D-aspartate (NMDA) receptor antagonist that is FDA-approved for general anesthesia.”
> “The Work Group’s confidence in the quality of the evidence was low.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.5-3"></a>

### NICE guideline: esketamine nasal spray not recommended

> “Esketamine nasal spray is not recommended in NICE technology appraisal guidance for treating treatment-resistant depression.”

Source: [NICE (2022)](https://www.nice.org.uk/guidance/ng222/chapter/Recommendations)

<a id="topic-2.2.2.1.5-4"></a>

### ICER assessment: esketamine and intravenous ketamine as comparators for psilocybin

> “In patients with persistent symptoms, recommended options include esketamine (S-ketamine), ketamine (used off-label for TRD), or repetitive transcranial magnetic stimulation (rTMS”
> “Esketamine (SPRAVATO®, Janssen) / Intravenous (IV) ketamine, an anesthetic agent used off-label for TRD”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-2.2.2.1.5-5"></a>

### Esketamine FDA-approved indications, including monotherapy

> “SPRAVATO is a non-competitive N-methyl D-aspartate (NMDA) receptor antagonist indicated for the treatment of:”
> “Treatment-resistant depression (TRD) in adults, as monotherapy or in conjunction with an oral antidepressant.”
> “Indications and Usage (1) 01/2025”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-2.2.2.1.5-6"></a>

### Esketamine dosing in treatment-resistant depression

> “The recommended dosage of SPRAVATO for the treatment of TRD in adults as monotherapy or in conjunction with an oral antidepressant is shown in Table 1.”
> “Weeks 1 to 4: Administer twice per week Weeks 5 to 8: Administer once weekly Week 9 and after: Administer every 2 weeks or once weekly*”
> “Dosing frequency should be individualized to the least frequent dosing to maintain remission/response.”
> “Evidence of therapeutic benefit should be evaluated at the end of the induction phase to determine need for continued treatment.”
> “Nasal Spray: 28 mg of esketamine per device.”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-2.2.2.1.5-7"></a>

### Esketamine boxed warning

> “WARNING: SEDATION; DISSOCIATION; RESPIRATORY DEPRESSION; ABUSE AND MISUSE; and SUICIDAL THOUGHTS AND BEHAVIORS”
> “Because of the risks of sedation, dissociation, and respiratory depression, patients must be monitored for at least 2 hours at each treatment session, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting”
> “SPRAVATO has the potential to be abused and misused.”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-2.2.2.1.5-8"></a>

### Esketamine REMS and post-dose monitoring

> “SPRAVATO is available only through a restricted program under a REMS called the SPRAVATO REMS because of the risks of serious adverse outcomes from sedation, dissociation, respiratory depression, abuse and misuse”
> “Healthcare settings must be certified in the program and ensure that SPRAVATO is: − Only dispensed and administered in healthcare settings.”
> “Administered by patients under the direct observation of a healthcare provider and that patients are monitored by a healthcare provider for at least 2 hours after administration of SPRAVATO”
> “Pharmacies must be certified in the REMS and must only dispense SPRAVATO to healthcare settings that are certified in the program.”
> “During and after SPRAVATO administration at each treatment session, observe the patient for at least 2 hours until the patient is safe to leave”
> “Before SPRAVATO administration, instruct patients not to engage in potentially hazardous activities, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-2.2.2.1.5-9"></a>

### Esketamine adverse reactions, contraindications, and blood pressure monitoring

> “The most commonly observed adverse reactions (incidence ≥5% and at least twice that of placebo):”
> “TRD: dissociation, dizziness, nausea, sedation, vertigo, hypoesthesia, anxiety, lethargy, blood pressure increased, vomiting, feeling drunk, and headache.”
> “In clinical trials, 48% to 61% of SPRAVATO-treated patients developed sedation based on the Modified Observer’s Assessment of Alertness/Sedation scale (MOAA/S)”
> “61% to 84% of SPRAVATO-treated patients developed dissociative or perceptual changes based on the Clinician-Administered Dissociative States Scale”
> “Aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels) or arteriovenous malformation”
> “After dosing with SPRAVATO, reassess blood pressure at approximately 40 minutes (which corresponds with the Cmax) and subsequently as clinically warranted.”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-2.2.2.1.5-10"></a>

### Esketamine monotherapy study: change in MADRS total score at Day 28

> “patients in Study 3 were randomized in a 1:1:2 ratio to receive twice weekly doses of intranasal SPRAVATO 56 mg or 84 mg or intranasal placebo for four weeks.”
> “SPRAVATO 56 mg and 84 mg monotherapy demonstrated statistical superiority on the primary efficacy measure compared to placebo nasal spray”
> “SPRAVATO (56 mg)† 86 37.5 (5.2) -11.4 (1.2) -5.1 (-7.9; -2.3) SPRAVATO (84 mg)† 95 36.6 (4.5) -13.0 (1.2) -6.8 (-9.5; -4.1) Placebo nasal spray 197 37.5 (4.9) -6.3 (0.8)”
> “The effect of SPRAVATO (56 mg and 84 mg) was observed at Day 2 (approximately 24 hours) and remained through Day 28.”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-2.2.2.1.5-11"></a>

### TRANSFORM-2: esketamine plus a new oral antidepressant at Day 28

> “The study enrolled adults with moderate to severe nonpsychotic depression and a history of nonresponse to at least two antidepressants in the current episode, with one antidepressant assessed prospectively.”
> “Of 435 patients screened, 227 underwent randomization and 197 completed the 28-day double-blind treatment phase.”
> “Change in MADRS score with esketamine plus antidepressant was significantly greater than with antidepressant plus placebo at day 28 (difference of least square means=-4.0, SE=1.69, 95% CI=-7.31, -0.64)”
> “7% and 0.9% of patients in the respective treatment groups discontinued study drug because of an adverse event.”

Source: [Popova et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31109201/)

<a id="topic-2.2.2.1.5-12"></a>

### TRANSFORM-3: esketamine in adults aged 65 years and older

> “For the primary endpoint, the median-unbiased estimate of the treatment difference (95% CI) was -3.6 (-7.20, 0.07); weighted combination test using MMRM analyses z = 1.89, two-sided p = 0.059.”
> “Esketamine/antidepressant did not achieve statistical significance for the primary endpoint.”

Source: [Ochs-Ross et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31734084/)

<a id="topic-2.2.2.1.5-13"></a>

### SUSTAIN-1: relapse prevention with continued esketamine

> “Among the 297 adults (mean age [SD], 46.3 [11.13] years; 197 [66.3%] female) who entered the randomized maintenance phase, 176 achieved stable remission; 24 (26.7%) in the esketamine and antidepressant group and 39 (45.3%) in the antidepressant and placebo group experienced relapse (log-rank P = .003, number needed to treat [NNT], 6).”
> “Esketamine and antidepressant treatment decreased the risk of relapse by 51% (hazard ratio [HR], 0.49; 95% CI, 0.29-0.84) among patients who achieved stable remission and 70% (HR, 0.30; 95% CI, 0.16-0.55) among those who achieved stable response compared with antidepressant and placebo treatment.”

Source: [Daly et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6551577/)

<a id="topic-2.2.2.1.5-14"></a>

### SUSTAIN-3: long-term safety and maintenance of response

> “At the interim data cutoff (01 December 2020), 1148 participants were enrolled, 458 at induction and 690 at optimization/maintenance.”
> “Common treatment-emergent adverse events (≥20%) were headache, dizziness, nausea, dissociation, somnolence, and nasopharyngitis.”
> “with 35.6% and 46.1% of participants in remission (MADRS total score ≤12) at induction and optimization/maintenance endpoints, respectively.”
> “Serious adverse events were reported for 171 (14.9%) of the 1148 participants during SUSTAIN-3, over 2769 cumulative patient-years.”

Source: [Zaki et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10267177/)

<a id="topic-2.2.2.1.5-15"></a>

### ESCAPE-TRD: esketamine compared with extended-release quetiapine augmentation

> “Overall, 336 patients were assigned to the esketamine group and 340 to the quetiapine group.”
> “More patients in the esketamine group than in the quetiapine group had remission at week 8 (91 of 336 patients [27.1%] vs. 60 of 340 patients [17.6%]; P = 0.003) and had no relapse through week 32 after remission at week 8 (73 of 336 patients [21.7%] vs. 48 of 340 patients [14.1%]).”
> “In an open-label, single-blind (with raters unaware of group assignments), multicenter, phase 3b, randomized, active-controlled trial”

Source: [Reif et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37792613/)

<a id="topic-2.2.2.1.5-16"></a>

### ELEKT-D: intravenous ketamine compared with electroconvulsive therapy

> “During an initial 3-week treatment phase, patients received either ECT three times per week or ketamine (0.5 mg per kilogram of body weight over 40 minutes) twice per week.”
> “A total of 403 patients underwent randomization at five clinical sites; 200 patients were assigned to the ketamine group and 203 to the ECT group.”
> “A total of 55.4% of the patients in the ketamine group and 41.2% of those in the ECT group had a response (difference, 14.2 percentage points; 95% confidence interval, 3.9 to 24.2; P<0.001 for the noninferiority of ketamine to ECT).”
> “ECT was associated with musculoskeletal adverse effects, whereas ketamine was associated with dissociation.”

Source: [Anand et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37224232/)

<a id="topic-2.2.2.1.5-17"></a>

### Ketamine and esketamine: Cochrane meta-analysis

> “The evidence suggests that ketamine may result in an increase in response and remission compared with placebo at 24 hours odds ratio (OR) 3.94, 95% confidence interval (CI) 1.54 to 10.10; n = 185, studies = 7, very low-certainty evidence).”
> “Esketamine treatment likely results in a large increase in participants achieving remission at 24 hours compared with placebo (OR 2.74, 95% CI 1.71 to 4.40; n = 894, studies = 5, moderate-certainty evidence).”
> “The effects of ketamine lasted no more than one week after treatment and clearly disappeared after two weeks.”
> “Esketamine caused a lot more side effects than placebo.”

Source: [Dean et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434915/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
